RECURRENT NON-SMALL CELL LUNG CARCINOMA
Clinical trials for RECURRENT NON-SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo tested in fight against tough cancers
Disease control CompletedThis study tested whether combining an experimental drug (sEphB4-HSA) with an approved immunotherapy (pembrolizumab) could help control advanced lung or head/neck cancers that had worsened after standard chemotherapy. It involved 42 patients who received both drugs by IV infusion…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Vaccine-Immunotherapy combo tested in Tough-to-Treat lung cancer
Disease control CompletedThis study tested whether combining a cancer vaccine (TG4010) with an immunotherapy drug (nivolumab) could help control advanced non-small cell lung cancer in patients whose previous treatments had stopped working. The vaccine aims to train the immune system to recognize and atta…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested for Tough-to-Treat lung cancers
Disease control CompletedThis early-stage trial tested a combination of two existing drugs, auranofin and sirolimus, for patients with advanced or returning lung cancer who had no other standard treatments left. The main goals were to find the safest dose and see if the drugs could slow the cancer's grow…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Diabetes drug added to lung cancer treatment in groundbreaking trial
Disease control CompletedThis study tested whether adding the common diabetes medication metformin to standard chemotherapy and radiation could better control stage III non-small cell lung cancer. Researchers randomly assigned 170 patients with inoperable lung cancer to receive either the standard treatm…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC